Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBITDA: 2019-2025

Historic EBITDA for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Sep 2025 value amounting to $51.0 million.

  • Harmony Biosciences Holdings' EBITDA rose 8.88% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.5 million, marking a year-over-year increase of 50.06%. This contributed to the annual value of $145.6 million for FY2024, which is 12.83% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' EBITDA stood at $51.0 million, which was up 28.19% from $39.8 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' EBITDA ranged from a high of $87.8 million in Q3 2022 and a low of -$9.6 million during Q3 2021.
  • For the 3-year period, Harmony Biosciences Holdings' EBITDA averaged around $37.4 million, with its median value being $38.5 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 192.68% in 2021, then spiked by 1,012.62% in 2022.
  • Over the past 5 years, Harmony Biosciences Holdings' EBITDA (Quarterly) stood at $22.7 million in 2021, then skyrocketed by 113.68% to $48.5 million in 2022, then plummeted by 44.11% to $27.1 million in 2023, then spiked by 80.80% to $49.0 million in 2024, then increased by 8.88% to $51.0 million in 2025.
  • Its EBITDA was $51.0 million in Q3 2025, compared to $39.8 million in Q2 2025 and $45.7 million in Q1 2025.